• CRO Services
  • Working with us
  • Company
  • Ressources
  • News
  • Career
  • Fr / En
  • Contact us →
  • Home
  • Working with us
  • Ressources
  • Company
  • News
  • Career
  • Contact
Fr / En
By Service
  • Dermatology – picto dermatologie Dermatology →
  • Neurology & CNS – picto neurologie Neurology & CNS →
  • Cardiovascular – picto cardiovasculaire Cardiovascular →
  • Neurovascular & Stroke – picto neurovasculaire Neurovascular & Stroke →
By service
  • In Vitro Efficacy Study
  • In Vivo Efficacy Study
  • Analytical services
  • Non-Regulatory Safety
  • PK/PD
  • Scientific consulting
By technology
  • High Content Imaging
  • Brain-on-Chip
  • Small & Large Animals
  • In Vivo Imaging
  • Biological Assays
  • Immunohistochemistry & Histology
  • Dermatology – picto dermatologie Dermatology →
  • Neurology & CNS – picto neurologie Neurology & CNS →
  • Cardiovascular – picto cardiovasculaire Cardiovascular →
  • Neurovascular & Stroke – picto neurovasculaire Neurovascular & Stroke →
By service
  • In Vitro Efficacy Study
  • In Vivo Efficacy Study
  • Analytical services
  • Non-Regulatory Safety
  • PK/PD
  • Scientific consulting
By technology
  • High Content Imaging
  • Brain-on-Chip
  • Small & Large Animals
  • In Vivo Imaging
  • Biological Assays
  • Immunohistochemistry & Histology
  • tMCAO model by autologous clot injection

    Injecting sizecalibrated autologous blood clots induces embolic occlusion of the proximal MCA segment. This model produces cortical and subcortical lesions similar to those observed in mechanical ischemia models. Mortality, deficit severity, and responsiveness to the reference fibrinolytic treatment (Alteplase) can be modulated by adjusting the amount of thrombotic material used for the embolic event. This original and wellcharacterized model enables the evaluation of a wide range of therapeutic strategies, together with longterm monitoring of functional recovery.

    ICH induced by collagenase injection Stereotaxic injection of collagenase rapidly disrupts the vascular endothelium, inducing a reproducible hemorrhage with the formation of an intracerebral hematoma, accompanied by an inflammatory response and clear neurological deficits. This ICH model provides a valuable translational tool for assessing the efficacy of your drug candidates on bleeding, neuroinflammation, and neuroprotection. Depending on your needs, it also offers the possibility to evaluate the risk of rebleeding or the effectiveness of antidotes across a panel of reference anticoagulants and fibrinolytics.

    Validated model available in rats

  • ICH induced by collagenase injection

    Stereotaxic injection of collagenase rapidly disrupts the vascular endothelium, inducing a reproducible hemorrhage with the formation of an intracerebral hematoma, accompanied by an inflammatory response and clear neurological deficits. This ICH model provides a valuable translational tool for assessing the efficacy of your drug candidates on bleeding, neuroinflammation, and neuroprotection. Depending on your needs, it also offers the possibility to evaluate the risk of rebleeding or the effectiveness of antidotes across a panel of reference anticoagulants and fibrinolytics.

  • ICH induced by autologous blood injection

    Stereotaxic infusion of a predetermined volume of autologous blood into the striatum generates a reproducible hematoma, inducing increased intracranial pressure, brain toxicity, and an inflammatory response associated with clear neurological deficits. This model provides a reliable tool for evaluating the efficacy of your drug candidates on edema, inflammation, or neuroprotection, while eliminating potential biases linked to their effects on bleeding volume.

    Stereotaxic infusion of a predetermined volume of autologous blood into the striatum generates a reproducible hematoma, inducing increased intracranial pressure, cerebral toxicity, and an inflammatory response associated with clear neurological deficits. This model is a reproducible tool for evaluating the efficacy of your molecules on edema, inflammation, or neuroprotection, eliminating potential biases related to their effect on bleeding volume.

    Validated model available in rats.

Previous Page
1 2 3
Logo
Home Our services Working with us Company
News Career Contact
FrançaisEnglish
ETAP SA (Head office)
13, rue du Bois de la Champelle
54500 Vandœuvre-lès-Nancy
FRANCE
Phone no.:
+33 (0)383 444 635
Contact us →
Subscribe to our newsletter and get all our latest news.
GET OUR NEWSLETTERS
LinkedIn
Legal Notice · Design by Thibaut Marquis · Dev by Yann Sainty · Capital ETAP SA 45737 €
ETAP-LAB
Manage consent
To provide the best experiences, we use technologies such as cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate interest purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or solely for the purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate interest purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. In the absence of a subpoena, voluntary compliance from your Internet Service Provider, or additional records from a third party, the information stored or retrieved for this sole purpose cannot generally be used to identify you.
Marketing
The technical storage or access is required to create user profiles in order to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}